The latest price target for Immunome (NASDAQ:IMNM) was reported by Piper Sandler on November 14, 2024. The analyst firm set a price target for $21.00 expecting IMNM to rise to within 12 months (a possible 112.73% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Immunome (NASDAQ:IMNM) was provided by Piper Sandler, and Immunome maintained their overweight rating.

There is no last upgrade for Immunome

There is no last downgrade for Immunome.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunome, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunome was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Immunome (IMNM) rating was a maintained with a price target of $23.00 to $21.00. The current price Immunome (IMNM) is trading at is $9.87, which is out of the analyst’s predicted range.